TY  - GEN
AU  - Provencio, Mariano
AU  - Terrasa, Josefa
AU  - Garrido, Pilar
AU  - Campelo, Rosario García
AU  - Aparisi, Francisco
AU  - Diz, Pilar
AU  - Aguiar, David
AU  - García-Giron, Carlos
AU  - Hidalgo, Julia
AU  - Aguado, Carlos
AU  - González, Jorge García
AU  - Esteban, Emilio
AU  - Gómez-Aldavarí, Lorenzo
AU  - Moran, Teresa
AU  - Juan, Oscar
AU  - Chara, Luís Enrique
AU  - Marti, Juan L
AU  - Castro, Rafael López
AU  - Ortega, Ana Laura
AU  - Moreno, Elia Martínez
AU  - Coves, Juan
AU  - Sánchez Peña, Ana M
AU  - Bosch-Barrera, Joaquim
AU  - Gastaldo, Amparo Sánchez
AU  - Núñez, Natalia Fernández
AU  - Del Barco, Edel
AU  - Cobo, Manuel
AU  - Isla, Dolores
AU  - Majem, Margarita
AU  - Navarro, Fátima
AU  - Calvo, Virginia
PY  - 2021
DO  - 10.1186/s12885-021-07922-5
UR  - http://hdl.handle.net/20.500.12105/18281
AB  - AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience...
LA  - eng
KW  - EGFR-activating mutations
KW  - Non-small cell lung cancer
KW  - Osimertinib
KW  - Real-world data
KW  - Second line
KW  - T790M EGFR mutation
KW  - Acrylamides
KW  - Adult
KW  - Aged
TI  - Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
TY  - research article
ER  -